T1	Participants 57 142	patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT.
T2	Participants 309 354	patients with poor left-ventricular function.
T3	Participants 692 722	patients at high risk of death
T4	Participants 1280 1365	EMIAT enrolled 1486 patients (743 in the amiodarone group, 743 in the placebo group).
T5	Participants 1418 1502	(103 deaths in the amiodarone group, 102 in the placebo group) and cardiac mortality
